Rallybio Corporaton (RLYB) Stock Price, Quote & News

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The c...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 859 3820

Website: www.rallybio.com

Address:

234 Church Street, New Haven, United States

SuperGreenToday May. 12 at 1:48 PM

$RLYB

0 · Reply

AlertsAndNews May. 7 at 2:42 AM

$RLYB 10%er buy here Daniel Schneeberger (10%+) purchased 155,905 shares at an average price of $13.97 (Form 4).

1 · Reply

Hedgieguy75 May. 6 at 6:51 PM

$RLYB Here she goes .. $16.50-75 $AHMA degens have a look $EVC degens also have a look

0 · Reply

InTheMoney_ May. 6 at 6:00 PM

$SPY $QQQ ---> $RLYB very high squeeze potential. Borrow rate is spiking. Very high short interest. Price up 60% in the last 5 days. Days to cover is at 20. finshort.com/RLYB

1 · Reply

Hedgieguy75 May. 6 at 2:39 PM

$RLYB one of the best short squeeze set ups .. 14.05 avg Over $14.50 look out! ... $AHMA degens have a look

0 · Reply

Joby099 May. 6 at 1:11 PM

$PN $CNSP $GBTG $RLYB

0 · Reply

Joby099 May. 6 at 8:10 AM

$PN $CNSP $GBTG $RLYB He killin it!! Solid call!!

0 · Reply

Joby099 May. 5 at 5:44 PM

$PN $CNSP $GBTG $RLYB He called it! Great work!

0 · Reply

CantNameThatTune May. 5 at 7:25 AM

$FCHL Look what they just did to $SKK $HCAI $PN $RLYB Isn't that what they do? Kill 'em and kill 'em and then suddenly up 500%-1000% out of nowhere? Yesterday should have told you it's coming on FCHL

0 · Reply

frankyboyz May. 5 at 7:16 AM

Support and retweet: #frankysWL The one and only Franky’s Watchlist May. 5, 2026 Edition TAU - Trend Analytics classes starting soon in March. Come check this out: https://trendanalytics.com/tau “Afterhours Movers, where tomorrow’s runners are born.” ━━━━━━━━━━━━━━━━━━━━━ $MASK.X $INHD $RLYB https://x.com/frankyboyz/status/2051561352297140257 Franky

0 · Reply

Rallybio, Candid Therapeutics announce merger agreement

Mar 2, 2026, 8:03 AM EST - 2 months ago

Rallybio Transcript: M&A announcement

Mar 2, 2026, 8:00 AM EST - 2 months ago

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Feb 17, 2026, 8:00 AM EST - 3 months ago

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

2026-02-06T00:50:24.000Z - 3 months ago

Rallybio Corp trading halted, news pending

2026-02-03T21:12:02.000Z - 3 months ago

Rallybio announces reverse 1-for-8 stock split

Feb 3, 2026, 4:05 PM EST - 3 months ago

Rallybio Announces Reverse Stock Split of Common Stock

Jan 26, 2026, 10:00 AM EST - 3 months ago

Rallybio Transcript: EGM 2026

Nov 6, 2025, 8:00 AM EST - 6 months ago

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

2025-09-25T12:05:58.000Z - 8 months ago

Rallybio completes dosing of first cohort in RLYB116 study

Sep 25, 2025, 8:00 AM EDT - 8 months ago

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

2025-09-03T12:15:52.000Z - 9 months ago

Rallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals

RXRX

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

2025-07-09T01:12:00.000Z - 11 months ago

Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement

RXRX

2025-07-08T12:16:04.000Z - 11 months ago

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

RXRX

2025-07-08T12:10:57.000Z - 11 months ago

Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102

RXRX

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

2025-06-12T12:10:19.000Z - 11 months ago

Rallybio initiates dosing in RLYB116 study

Jun 12, 2025, 8:00 AM EDT - 11 months ago

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

2025-05-08T12:38:24.000Z - 1 year ago

Rallybio reports Q1 EPS (21c), consensus (28c)

May 8, 2025, 8:00 AM EDT - 1 year ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025, 12:00 PM EDT - 1 year ago

Rallybio Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

2025-04-14T20:25:23.000Z - 1 year ago

Rallybio downgraded to Hold from Buy at JonesResearch

2025-04-11T19:55:13.000Z - 1 year ago

Rallybio downgraded to In Line from Outperform at Evercore ISI

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 1:10 PM EST - 1 year ago

Rallybio Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 11, 2025, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Jan 10, 2025, 8:00 AM EST - 1 year ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Dec 10, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 4, 2024, 12:30 PM EST - 1 year ago

Rallybio Transcript: 7th Annual Evercore HealthCONx Conference

Dec 2, 2024, 8:30 AM EST - 1 year ago

Rallybio Transcript: Status Update

Dec 2, 2024, 8:00 AM EST - 1 year ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Nov 27, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 25, 2024, 8:00 AM EST - 1 year ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 21, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 7, 2024, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 9, 2024, 5:15 PM EDT - 1 year ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 27, 2024, 8:00 AM EDT - 1 year ago

National Vision Releases 2023 Sustainability Report

ACNT

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 9, 2024, 8:00 AM EDT - 2 years ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

May 9, 2024, 8:00 AM EDT - 2 years ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 8:00 AM EDT - 2 years ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Apr 17, 2024, 4:01 PM EDT - 2 years ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 10, 2024, 4:01 PM EDT - 2 years ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 1, 2024, 10:05 AM EDT - 2 years ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 8:00 AM EST - 2 years ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Jan 10, 2024, 11:15 AM EST - 2 years ago

Rallybio Transcript: J.P. Morgan 42nd Annual Healthcare Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Dec 20, 2023, 8:30 AM EST - 2 years ago

Rallybio Transcript: Study Update

Dec 20, 2023, 8:00 AM EST - 2 years ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Dec 9, 2023, 12:00 PM EST - 2 years ago

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Nov 28, 2023, 7:00 AM EST - 2 years ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Nov 9, 2023, 8:00 AM EST - 2 years ago

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 8:00 AM EST - 2 years ago

Rallybio to Present at Upcoming Investor Conferences in November

SuperGreenToday May. 12 at 1:48 PM

$RLYB

0 · Reply

AlertsAndNews May. 7 at 2:42 AM

$RLYB 10%er buy here Daniel Schneeberger (10%+) purchased 155,905 shares at an average price of $13.97 (Form 4).

1 · Reply

Hedgieguy75 May. 6 at 6:51 PM

$RLYB Here she goes .. $16.50-75 $AHMA degens have a look $EVC degens also have a look

0 · Reply

InTheMoney_ May. 6 at 6:00 PM

$SPY $QQQ ---> $RLYB very high squeeze potential. Borrow rate is spiking. Very high short interest. Price up 60% in the last 5 days. Days to cover is at 20. finshort.com/RLYB

1 · Reply

Hedgieguy75 May. 6 at 2:39 PM

$RLYB one of the best short squeeze set ups .. 14.05 avg Over $14.50 look out! ... $AHMA degens have a look

0 · Reply

Joby099 May. 6 at 1:11 PM

$PN $CNSP $GBTG $RLYB

0 · Reply

Joby099 May. 6 at 8:10 AM

$PN $CNSP $GBTG $RLYB He killin it!! Solid call!!

0 · Reply

Joby099 May. 5 at 5:44 PM

$PN $CNSP $GBTG $RLYB He called it! Great work!

0 · Reply

CantNameThatTune May. 5 at 7:25 AM

$FCHL Look what they just did to $SKK $HCAI $PN $RLYB Isn't that what they do? Kill 'em and kill 'em and then suddenly up 500%-1000% out of nowhere? Yesterday should have told you it's coming on FCHL

0 · Reply

frankyboyz May. 5 at 7:16 AM

0 · Reply

AngelCapital May. 5 at 5:34 AM

$RLYB back to 11 and 12 down open

0 · Reply

Joby099 May. 5 at 3:13 AM

$PN $CNSP $GBTG $RLYB

0 · Reply

thatsabingo1 May. 5 at 3:03 AM

$RLYB folks this thing jumped PM if it was going to 18/20+ it would have done so today. Will definitely short tomorrow

0 · Reply

thatsabingo1 May. 5 at 3:01 AM

$RLYB literally anything this guy shills is a dud.

0 · Reply

Sw1ngb0t May. 5 at 12:58 AM

$RLYB $18+

2 · Reply

zerodayrounder May. 4 at 11:46 PM

$RLYB they already decided to shut down Rallybio. I think they will probably hold themself out as a public cash shell for a different private biotech to go public with in a reverse merger.

0 · Reply

topstockalerts May. 4 at 10:50 PM

Top Gainers PT2 $GBTG $CRE $HCAI $RLYB $ABVE

0 · Reply

RichardCraniumWozEre May. 4 at 9:05 PM

$RLYB Schwing G'night

0 · Reply

NoteToSelf5000 May. 4 at 8:57 PM

$RLYB Merger agreement terminated after which the company will receive a $50M termination fee. The market cap is only $50M. Tiny float! Looks like it’s getting ready to run. Maybe there might be a special dividend for shareholders? https://www.otcmarkets.com/filing/html?id=19404143&guid=35v-kHfQUoTdB3h

0 · Reply

frankyboyz May. 4 at 8:46 PM

keeping an eye for continuation tomorrow if these ah taps go on $RLYB

0 · Reply

InvestingSpaceman May. 4 at 8:35 PM

$HCAI $RLYB ///

0 · Reply

topstockalerts May. 4 at 8:04 PM

$RLYB this might be one of those “why didn’t I take it” later

1 · Reply

Market Cap	74.06M
Revenue (ttm)	860,000.00
Net Income (ttm)	-8.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,044.19%
Debt to Equity Ratio	0.00

Volume	87,700
Avg Vol	325,274
Day's Range	N/A - N/A
Shares Out	5.29M
Stochastic %K	81%
Beta	-1.10
Analysts	Hold
Price Target	$8.00